Free Trial
NASDAQ:CLDX

Celldex Therapeutics Q1 2025 Earnings Report

Celldex Therapeutics logo
$19.49 -0.35 (-1.76%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$19.76 +0.27 (+1.39%)
As of 05/30/2025 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celldex Therapeutics EPS Results

Actual EPS
-$0.81
Consensus EPS
-$0.75
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Celldex Therapeutics Revenue Results

Actual Revenue
$0.70 million
Expected Revenue
$1.08 million
Beat/Miss
Missed by -$384.00 thousand
YoY Revenue Growth
N/A

Celldex Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Celldex Therapeutics' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Celldex Therapeutics Earnings Headlines

“You all just got a lot richer”
Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.
See More Celldex Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celldex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celldex Therapeutics and other key companies, straight to your email.

About Celldex Therapeutics

Celldex Therapeutics (NASDAQ:CLDX), a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

View Celldex Therapeutics Profile

More Earnings Resources from MarketBeat